Waters Corporation WAT reported first-quarter 2019 non-GAAP earnings of $1.6 per share, missing the Zacks Consensus Estimate by 13 cents. The figure increased 0.6% on a year-over-year basis but declined 44.2% sequentially.
Net sales came in $513.9 million, lagging the Zacks Consensus Estimate of $545.5 million. Further, the figure was down 3% year over year and 28.1% from the previous quarter.
Lower-than-expected results can primarily be attributed to adverse effects of foreign exchange fluctuations and macro-economic headwinds in China and Europe.
Further, weak demand environment throughout the quarter especially in the pharmaceutical and industrial market due to sluggish customer spending affected the sales figure.
Coming to the price performance, shares of Waters have returned 5.9% over a year, underperforming the industry’s rally of 21.9%.
Nevertheless, the company remains optimistic about its strengthening growth initiatives and new product introductions which are likely to aid it in gaining investors’ confidence in the near term.
Top Line in Detail
Waters’ net sales figure can be categorized in four ways:
By Operating Segment: The company operates in two organized segments — Waters and TA.
Waters segment (89.5% of net sales) generated $459.91 million of sales, down 2% from the year-ago quarter. Sales in TA segment came in $53.95 million and accounted for 10.5% of the net sales. The figure reflected year-over-year decline of 9%.
By Products & Services: This division comprises three segments — Instruments, Services and Chemistry.
Instruments sales (43.1% of sales) came in $221.25 million, down 8% on a year-over-year basis.
Service sales (37.6% of the sales) were $193.36 million. The figure increased 1% year over year.
Chemistry sales (19.3% of the sales) were $99.25 million, increasing 1% from the year-ago quarter.
Moreover, service and chemistry sections together generated recurring revenues of $292.61 million, up 1% from the year-ago quarter.
By Markets: The company serves three end markets — Pharmaceutical, Industrial and Governmental & Academic.
Pharmaceutical market (57.3% of net sales) generated sales of $294.51 million, down 4% on a year-over-year basis.
Industrial market (30.2% of sales) sales came in $155.22 million, down 4% from the year-ago quarter.
Governmental & Academic (12.5% of sales) generated $64.13 million of sales. The figure was up 2% year over year.
By Geography: This company’s operating regions include Asia, Americas and Europe.
Asia (39% of net sales) generated $200.51 million of sales for the company. The figure was up 0.1% on a year-over-year basis.
Americas (35.4% of sales) generated $181.87 million of sales, remaining flat year over year.
Europe (25.6% of sales) generated $131.48 million of sales, down 12% from prior-year quarter.
Waters Corporation Price, Consensus and EPS Surprise
Waters Corporation Price, Consensus and EPS Surprise | Waters Corporation Quote
In the first quarter, non-GAAP selling and administrative expenses were $124.3 million, suggesting a decline of 3.5% from the year-ago quarter.
Further, research and development spending was $35.1 million, indicating a decline of 1.7% form the year-ago reported figure.
Adjusted operating margin was 26%, contracting 150 basis points (bps) from the year-ago quarter.
Balance Sheet & Cash Flow
As of Mar 30, 2019, cash, cash equivalents and investments came in $1.17 billion, lower than $1.73 billion as of Dec 31, 2018.
Further, total liabilities were $2.28 billion, increasing from $2.16 billion in the previous quarter.
Waters also generated free cash flow of $157.61 million in the fourth quarter.
For second-quarter 2019, Waters expects non-GAAP earnings in the range of $2.05-$2.15 per share. The Zacks Consensus Estimate for earnings is pegged at $2.23.
The company anticipates net sales growth between 2% and 4% on a constant currency basis. The Zacks Consensus Estimate for sales is currently projected at $612.63 million.
For 2019, Waters lowered guided range for non-GAAP earnings from $9.20-$9.45 per share to $9.05-$9.25 per share. The Zacks Consensus Estimate for 2019 earnings is pegged at $9.35 per share.
Further, the company guided net sales growth in the band of 2-4% on a constant currency basis, lower than the previously anticipated range of 4-6%. The Zacks Consensus Estimate for sales is pegged at $2.51 billion.
Zacks Rank & Stocks to Consider
Currently, Waters carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader technology sector are Fortive FTV, Mettler-Toledo International MTD and AMETEK AME. While Fortive flaunts a Zacks Rank #1 (Strong Buy), Mettler-Toledo International and AMETEK carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rate for Fortive, Mettler-Toledo International and AMETEK is currently pegged at 11.94%, 12.57% and 9.58%, respectively.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Mettler-Toledo International, Inc. (MTD) : Free Stock Analysis Report
Waters Corporation (WAT) : Free Stock Analysis Report
AMETEK, Inc. (AME) : Free Stock Analysis Report
Fortive Corporation (FTV) : Free Stock Analysis Report
To read this article on Zacks.com click here.